

Anthera Pharmaceuticals Inc
 Form 4
 July 01, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 TRUEX PAUL F

2. Issuer Name and Ticker or Trading Symbol
 Anthera Pharmaceuticals Inc
 [ANTH]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 25801 INDUSTRIAL BLVD SUITE B
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 06/30/2014

____ Director
 ____ 10% Owner
 ____ Officer (give title below) ____ Other (specify below)
 President and CEO

HAYWARD, CA 94545

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	
Common Stock	06/30/2014		M		2,000	A	\$ 2.08 13,845 D
Common Stock	06/30/2014		F		699 ⁽¹⁾	D	\$ 3.39 ₍₂₎ 14,709 D
Common Stock	06/30/2014		G ⁽³⁾		16,500	D	\$ 0 62,128 I By Trust
Common Stock	06/30/2014		J ⁽⁴⁾		14,709	D	\$ 0 14,709 I By Trust

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 3 and 4)
				Code V (A) (D)		Date Exercisable Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRUEX PAUL F 25801 INDUSTRIAL BLVD SUITE B HAYWARD, CA 94545			President and CEO	

Signatures

/s/ Paul Truex 07/01/2014

__Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Shares forfeited in lieu of payment of tax liability in connection with the vesting of 1,562 Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. These shares were incorrectly included in the Reporting Person's indirect ownership but corrected as shown above.
- (1) Person, which are subject to certain vesting conditions. These shares were incorrectly included in the Reporting Person's indirect ownership but corrected as shown above.
 - (2) The number of shares forfeited by the Reporting Person was based on the closing price of the Issuer's common stock on June 30, 2014 the vesting date of the 2010 Grant
 - (3) This transaction involved a gift of securities by the Reporting Person to his children's trust, The 2006 Truex Irrevocable Trust, u/d/t April 6, 2006 (the "2006 Trust"), who shares Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by the 2006 Trust, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of the 2006 Trust's shares for purposes of Section 16 or for any other purpose.

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

(4) On June 30, 2014, the Reporting Person transferred 14,709 shares to the 2005 Truex Family Trust u/d/t April 20, 2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.